Leukogene Therapeutics key facts
- Operator of an oncology-focused biotech company intended to accelerate the development of new therapeutics for patients with advanced-stage cancer.
- Notable investors include SC Launch, South Carolina Research Authority, 1824 Health Ventures, U.S. Department of Health and Human Services.
- Status: Privately Held (backing).
Who backs Leukogene Therapeutics
4- ·Watch Leukogene Therapeutics: the Monday email on marks, rounds and moves
Leukogene Therapeutics funding rounds
No funding rounds for Leukogene Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Leukogene Therapeutics investors
4 investors are on record for Leukogene Therapeutics, including SC Launch, South Carolina Research Authority, 1824 Health Ventures and U.S. Department of Health and Human Services.
About Leukogene Therapeutics
Operator of an oncology-focused biotech company intended to accelerate the development of new therapeutics for patients with advanced-stage cancer. The company offers patients with resistant multiple myeloma a new therapeutic avenue, enabling patients to easily treat cancer without any surgery.
- Sector
- Healthcare
- HQ
- Charleston, SC, United States
- Founded
- 2012
- Employees
- 5
- Website
- leukogene.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Leukogene Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.